Nov 10 (Reuters) - Theratechnologies Inc TH.TO
* Theratechnologies inc says ibalizumab maintains significant reduction of viral load in patients with multi-drug resistant hiv-1 over 24 weeks
* Theratechnologies inc says results from study support regulatory submission of bla to us fda
* Theratechnologies inc - phase iii trial confirms safety and efficacy results of ibalizumab observed in previously completed phase iib study
* Theratechnologies announces results from the last pivotal phase iii trial of hiv long acting biologic (lab) investigational antiretroviral ibalizumab. Source text for Eikon: ID:nCCN2TSB69 Further company coverage: TH.TO